Protocol Ledger

NCT04511013 · Phase II · RECRUITING

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Interventional Phase II clinical trial protocol NCT04511013 sponsored by SWOG Cancer Research Network in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-06 Enrollment: 112 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04511013
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)112 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04511013
Protocol FieldVerified Registry Value
NCT IdentifierNCT04511013
Consolidated Lead SponsorSWOG Cancer Research Network
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment112 participants (ESTIMATED)
Registered Start Date2021-01-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI